In another cliffhanger, the Dow Jones Industrials
Earlier today, I looked at three Dow stocks that turned out to be among the top performers today. So let me turn instead to some other gainers for Friday.
Drug giant Pfizer is in the process of trying to sell off its infant nutrition unit to focus more on its core business. Reports surfaced early today that Mead Johnson Nutrition, itself a spinoff from Bristol-Myers Squibb, plans to team up with France's Danone to make a bid for the business. With Nestle already expected to participate, a bidding war could be great news for Pfizer.
One potential hurdle is concentration in the baby formula market, which could raise anti-competitive concerns. With bids due in early March, you won't have to wait long to find out what happens next.
Procter & Gamble
The news wasn't so bright at consumer goods giant P&G. The company announced that it will nix 5,700 jobs as one component of a cost-cutting plan expected to try to trim as much as $10 billion. The cuts will represent a 10% drop in P&G's non-manufacturing job base.
From an investing standpoint, the move could help P&G be more competitive and boost shares. But as just another example of how this economic recovery hasn't been as supportive of new jobs as previous ones, P&G's news could fuel more criticism of government efforts to boost the economy, especially in this election year.
Overall, energy stocks got a boost from higher oil prices. But Exxon had particularly good news of its own.
The company said that it has discovered huge quantities of natural gas in an offshore find near the cost of Tanzania. Working with Statoil
Look beyond the Dow for even better investment prospects. We've got one stock we're especially excited about, as the Fool's chief investment officer picked it to crush the market. To learn more about it, check out this free report: "The Motley Fool's Top Stock for 2012." Instant access is just a click away.